NCT00394368已完成3 期
DOUBLE BLIND, MULTINATIONAL, MULTICENTRE, PARALLEL-GROUP DESIGN CLINICAL TRIAL OF THE EFFICACY AND TOLERABILITY OF CHF 1535 (BECLOMETHASONE DIPROPIONATE 100 µg + FORMOTEROL 6 µg) pMDI VIA HFA-134a vs. FLUTICASONE 125 µg + SALMETEROL 25 µg pMDI (SERETIDE®) IN THE 12-WEEK TREATMENT OF ADULT PATIENTS WITH MODERATE TO SEVERE PERSISTENT ASTHMA
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 180
- 试验地点
- 14
- 主要终点
- morning peak expiratory flow (PEF) daily measured by patients
研究概览
简要总结
The aim of this study was to compare the efficacy and tolerability of the fixed combination beclomethasone/formoterol pMDI with that of fluticasone/salmeterol pMDI in patients with moderate to severe asthma
详细描述
Asthma is a chronic disease that is estimated to affect over 25 million people both in the U.S. and Europe (i.e. approximately 10% of the total population). Pharmacological therapy is used to treat reversible airway obstruction, inflammation and hyper-reactivity. Medications include preventive treatments in forms of antinflammatory/antiallergic agents (i.e. glucocorticosteroids, leukotriene antagonists, cromolyn sodium) and reliever treatments, in form of bronchodilators (i.e. β-adrenergic agonists, anticholinergics). In patients treated with inhaled glucocorticosteroids whose asthma is not fully controlled, national and international guidelines recommend a stepwise approach. Recent evidence-based clinical trials show that the addition of a LABA to inhaled glucocorticosteroids is more beneficial in terms of asthma control than increasing the dose of corticosteroids alone.
Comparisons: CHF 1535 (BECLOMETHASONE DIPROPIONATE 100 µg + FORMOTEROL 6 µg) pMDI VIA HFA-134a compared to FLUTICASONE 125 µg + SALMETEROL 25 µg pMDI (SERETIDE®)
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Clinical diagnosis of moderate to severe persistent asthma for at least 6 months, according to GINA revised version 2002 guidelines (11):
- •Forced expiratory volume (FEV1) or peak expiratory flow rate (PEFR) ³ 50% and £ 80% of the predicted normal;
- •Asthma not adequately controlled with the current therapies, defined as presence of daily asthma symptoms > once a week and night-time asthma symptoms > twice a month, and daily use of short-acting β2-agonists. These findings are to be based on recent medical history and are to be confirmed in the 2-week run-in period.
- •Treatment with inhaled corticosteroids at a daily dose ≤ 1000 μg of BDP or equivalent. The daily dose of inhaled corticosteroids taken at visit 1 will be assessed taking into account the following ratios between the doses of the different steroids: fluticasone propionate : BDP CFC = 1 : 2; budesonide : BDP CFC = 4 : 5; flunisolide : BDP CFC = 1 :
- •The ratios between inhaled steroids are irrespective of the formulations (i.e. spray aerosol or powder) used. When BDP is given in the new extra-fine HFA-134a formulation (as QVAR®, 3M Healthcare), the ratio with BDP CFC is set as 2 :
- •Therefore, the maximum allowed daily dose of inhaled corticosteroids at study entry will be: budesonide 800 μg, fluticasone propionate 500 μg, flunisolide 1000 μg, BDP 1000 mg, BDP HFA extra-fine 400 μg.
- •Positive response to the reversibility test in the screening visit, defined as an increase of at least 12% (or, alternatively, of 200mL) from baseline value in the measurement of FEV1 30 minutes following 2 puffs (2 ´ 100 µg) of inhaled salbutamol administered via pMDI. The reversibility test can be avoided in patients having a documented positive response in the previous 6 months.
- •A co-operative attitude and ability to be trained to correctly use the metered dose inhalers and to complete the diary cards.
- •Written informed consent obtained.
- •At the end of the 2-week run-in period, the presence of daily asthma symptoms (of at least mild intensity) and nighttime asthma symptom (of at least mild intensity) > once a week, as well as of daily use of relief salbutamol is to be confirmed by reviewing the diary cards for run-in.
排除标准
- •Inability to carry out pulmonary function testing;
- •Diagnosis of Chronic Obstructive Pulmonary Disease (COPD) as defined by the National Heart Lung and Blood Institute/World Health Organisation (NHLBI/WHO) Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines (30);
- •History of near fatal asthma;
- •Evidence of severe asthma exacerbation or symptomatic infection of the airways in the previous 8 weeks;
- •Three or more courses of oral corticosteroids or hospitalisation due to asthma during the previous 6 months;
- •Patients treated with long-acting β2-agonists, anticholinergics and antihistamines during the previous 2 weeks, with topical or intranasal corticosteroids and leukotriene antagonists during the previous 4 weeks;
- •Patients who have changed their dose of inhaled corticosteroids during the previous 4 weeks, or treatment with inhaled corticosteroids at a daily dose > 1000 μg of BDP or equivalent (except for extra-fine formulations, see inclusion criteria);
- •Current smokers or recent (less than one year) ex-smokers, defined as smoking at least 10 cigarettes/day;
- •History or current evidence of heart failure, coronary artery disease, myocardial infarction, severe hypertension, cardiac arrhythmias;
- •Diabetes mellitus;
- •Percutaneous transluminal coronary angioplasty (PTCA) or coronary artery by-pass graft (CABG) during the previous six months;
- •Patients with an abnormal QTc interval value in the ECG test, defined as > 450 msec in males or > 470 msec in females;
- •Other haemodynamic relevant rhythm disturbances (including atrial flutter or atrial fibrillation with ventricular response, bradycardia (≤ 55 bpm), evidence of atrial-ventricular (AV) block on ECG of more than 1st degree;
- •Clinically significant or unstable concurrent diseases: uncontrolled hyperthyroidism, significant hepatic impairment, poorly controlled pulmonary (tuberculosis, active mycotic infection of the lung), gastrointestinal (e.g. active peptic ulcer), neurological or haematological autoimmune diseases;
- •Cancer or any chronic diseases with prognosis < 2 years;
- •Pregnant or lactating females or females at risk of pregnancy, i.e. those not demonstrating adequate contraception (i.e. barrier methods, intrauterine devices, hormonal treatment or sterilization). A pregnancy test is to be carried out in women of a fertile age.
- •History of alcohol or drug abuse;
- •Patients treated with monoamine oxidase inhibitors, tricyclic antidepressants or beta-blockers as regular use;
- •Allergy, sensitivity or intolerance to study drugs and/or study drug formulation ingredients;
- •Patients unlikely to comply with the protocol or unable to understand the nature, scope and possible consequences of the study;
- •Patients who received any investigational new drug within the last 12 weeks;
- •Patients who have been previously enrolled in this study;
- •At the end of the run-in period, patients will not be admitted to the treatment period in the case of an increase of PEFR (L/sec) measured at the clinics at the end of the run-in period ³ 15% in respect of values measured at the start of the run-in period;
- •Patients with asthma exacerbations during the run-in period will also be excluded from the study.
结局指标
主要结局
morning peak expiratory flow (PEF) daily measured by patients
次要结局
- FEV1 measured by patients daily
- evening PEF measured by patients daily
- standard pulmonary function tests measured at clinics at 2, 4, 8 and 12 weeks
- symptoms scores measured by patients daily
- adverse events and adverse drug reactions daily
- ECG (with QTc interval) at 0 and 12 weeks
- vital signs (heart rate and blood pressure)at 2, 4, 8 and 12 weeks
- 12-hour (overnight)urinary cortisol/creatinine ratio at week 0 and 12
- symptoms' free days measured by patients daily
- use of relief salbutamol measured by patients daily
- frequency of asthma exacerbations evaluated at 2, 4, 8 and 12 weeks
- change in FEV1 and PEF from pre-dose to 5, 15, 30 and 60 minutes after study drug intake at week 0 and 12
研究者
研究点 (14)
Loading locations...
相似试验
已完成
3 期
Efficacy and Tolerability of Beclomethasone Dipropionate 100 µg + Formoterol 6 µg pMDI Via HFA-134a Vs. Budesonide 160 µg + Formoterol 4,5 µg Dry Powder Via Turbuhaler®. (Symbicort®)Bronchial AsthmaNCT00413387Chiesi Farmaceutici S.p.A.219
已完成
3 期
Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus RaltegravirHIV InfectionNCT00708162Gilead Sciences724
已完成
2 期
CyclASol for the Treatment of Moderate to Severe Dry-eye Disease (DED)Dry Eye SyndromesNCT02617667Novaliq GmbH207
已完成
3 期
Study of the Effectiveness of Three Different Doses of OPC-34712 in the Treatment of Adults With Acute SchizophreniaAcute SchizophreniaNCT01396421Otsuka Pharmaceutical Development & Commercialization, Inc.636
已完成
1 期
Phase I/II Trial of S64315 Plus Azacitidine in Acute Myeloid LeukaemiaAcute Myeloid LeukaemiaNCT04629443Institut de Recherches Internationales Servier17